Prostate cancer ranks fifth in cancer-related mortality in men worldwide. DNA damage is
implicated in cancer and DNA damage response (DDR) pathways are in place against this …

Large-scale chromatin features, such as replication time and accessibility influence the rate
of somatic and germline mutations at the megabase scale. This article reviews how local …

Circulating tumour DNA (ctDNA) in blood plasma is an emerging tool for clinical cancer
genotyping and longitudinal disease monitoring. However, owing to past emphasis on …

Epigenetic processes govern prostate cancer (PCa) biology, as evidenced by the
dependency of PCa cells on the androgen receptor (AR), a prostate master transcription …

We report the discovery of ARD-2051 as a potent and orally efficacious androgen receptor
(AR) proteolysis-targeting chimera degrader. ARD-2051 achieves DC50 values of 0.6 nM …

Objective Evidence shows that gene mutation is a significant proportion of genetic factors
associated with prostate cancer. The DNA damage response (DDR) is a signal cascade …

The search for natural and efficacious antineoplastic drugs, with minimal toxicity and side
effects, is an important part of antitumor drug research and development. Tanshinone IIA is …

Prostate cancer (PrCa) is the second most common cancer worldwide in males. While
strongly warranted, the prediction of mortality risk due to PrCa, especially before its …

The role of endocrine disruptors (EDs) in the human prostate gland is an overlooked issue
even though the prostate is essential for male fertility. From experimental models, it is known …

Androgen receptor (AR) drives prostate cancer (PCa) development and progression. AR
chromatin binding profiles are highly plastic and form recurrent programmatic changes that …